Evidence map›Paper›PMID 39731402›Full record

Observational studyClinical & experimental ophthalmology

Outliers of Treatment Frequency in Retinal Vein Occlusion: 24-Month Comparative Analysis of Fight Retinal Blindness! Practitioners.

Theodorus Ponsioen, Yohei Hashimoto, Alessandro Invernizzi, Pierre-Henry Gabrielle, Francisco Javier Lavid, Hemal Mehta, Rufino Silva, Nandor Jaross, David Squirrell, Louise O'Toole and 4 more

Abstract readMulticenter StudyObservational StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical & experimental ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Theodorus PonsioenDepartment of Ophthalmology, Isala, Zwolle, The Netherlands.
Yohei HashimotoThe Save Sight Institute, Sydney Medical School, the University of Sydney, Sydney, New South Wales, Australia.
Alessandro InvernizziThe Save Sight Institute, Sydney Medical School, the University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-3400-1987
Pierre-Henry GabrielleThe Save Sight Institute, Sydney Medical School, the University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-9688-4845
Francisco Javier LavidDepartment of Ophthalmology, Hospital Punta Europa, Algeciras, Cádiz, Spain.
Hemal MehtaThe Save Sight Institute, Sydney Medical School, the University of Sydney, Sydney, New South Wales, Australia.
Rufino SilvaFaculty of Medicine, University of Coimbra, Coimbra, Portugal.
Nandor JarossAustralian Eye Specialists (Wyndham), Werribee, Victoria, Australia.
David SquirrellAuckland District Health Board, Auckland, New Zealand.
Louise O'TooleMater Private Hospital, Dublin, Ireland.
Pavol KusendaDepartment of Ophthalmology, University Hospital-St. Michael's Hospital, Bratislava, Slovakia.
Daniel BarthelmesDepartment of Ophthalmology, University Hospital and University of Zurich, Zurich, Switzerland.
Mark GilliesThe Save Sight Institute, Sydney Medical School, the University of Sydney, Sydney, New South Wales, Australia.
Adrian HuntThe Save Sight Institute, Sydney Medical School, the University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-6261-4679

Funding

Bayer FoundationNational Health and Medical Research Council NHMRC 2010-1012Novartis Pharmaceuticals CorporationRoyal Australian and New Zealand College of Ophthalmologists 2007-2009
6 · The paper itself

Abstract

backgroundWe aimed to describe a 2-year outcome of eyes managed by practitioners benchmarked using a funnel plot by their frequency of treatment using vascular endothelial growth factor (VEGF) inhibitors for naive retinal vein occlusion (RVO).

methodsA multicentre, international, observational study of 29 doctors in 12 countries managing 1110 eyes with RVO commencing VEGF inhibitors between 1 January 2012-2022 tracked in the Fight Retinal Blindness! registry.

resultsWe identified 3 outlying 'intensive' practitioners (managing 350/1110 eyes [32%]), 22 'typical' practitioners (604/1110, [54%]) and 4 outlying 'relaxed' practitioners (156/1110, [14%]) with respective 24-month outcomes in Branch and Central RVO including the primary outcome, mean adjusted change in visual acuity (VA) in BRVO: +16.2, +13.6, +9.3 letters (p < 0.01) and CRVO: +14.2, +12.7, +4.8 letters (p < 0.01); adjusted change in macular thickness in BRVO -179, -150, -159 μm (p < 0.01) and CRVO -324, -283, -232 μm (p < 0.01); time-in-range with VA > 68 letters in BRVO 90, 78, 68 weeks (p < 0.01) and CRVO 69, 60, 54 weeks (p = 0.04); median injections 18, 13 and 10; median final injection intervals, BRVO 6, 9, 10 weeks and CRVO 6, 9 and 12 weeks; with no significant difference in adverse outcomes.

conclusionsAt 24 months, the intensive practitioners were treating RVO using VEGF inhibitors with twice the frequency of the relaxed practitioners; however, their patients had gained twice (BRVO) to three times (CRVO) more letters of VA.

Indexed as

Angiogenesis InhibitorsBlindnessPractice Patterns, Physicians'Retinal Vein OcclusionAgedBevacizumabFemaleFollow-Up StudiesHumansIntravitreal InjectionsMaleMiddle AgedRanibizumabRegistriesTime FactorsTomography, Optical CoherenceAngiogenesis InhibitorsBevacizumabRanibizumabVascular Endothelial Growth Factor AVEGFA protein, humanBRVOCRVOmaculaocclusionoedemaretinaltreatment frequencyvein

Identifiers

PMID39731402
PMCPMC12129715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.